Name: 글로벌 시장 동향
SKU: BT12
Availability: InStock

보고서 요약(국문)

시장 개요
글로벌 단일클론항체 치료제 시장은 2022년 1,906억 9,830만 달러에 달했으며, 2030년까지 5,313억 1,460만 달러에 이르러 높은 성장세를 보일 것으로 예상됩니다. 글로벌 단일클론항체 치료제 시장은 예측 기간(2023-2030년) 동안 연평균 14.1%의 성장률을 기록할 것으로 전망됩니다.
단일클론항체 치료제(mAb)는 동일한 항체(또는 항체 단편)를 사용하여 균일한 방식으로 제조됩니다. 제품에 포함된 모든 항체 분자는 항원 인식 부위, 생물학적 상호작용, 친화도 및 하위 생물학적 효과가 동일합니다. 이는 다양한 단백질 서열과 에피토프 인식을 갖는 다클론 항체와 단일클론 항체를 구분하는 특징입니다.
단일클론 항체 치료제의 세계 시장은 자가면역 질환의 유병률 증가, 치료제 파이프라인의 규모 확대, 바이오제약 회사의 투자 및 여러 국가에서의 향후 의약품 승인 등 여러 요인으로 인해 성장하고 있으며, 이러한 요인들은 단일클론 항체 치료제 시장 성장에 긍정적인 전망을 제시하고 있습니다.
시장 동향
규제 승인 증가 및 치료제 출시가 단일클론 항체 치료제 시장 성장을 견인
암 또는 자가면역 질환 치료에 사용되는 다양한 단일클론 항체 치료제에 대한 여러 규제 기관의 승인 증가, 주요 바이오제약 회사의 임상 시험 증가, 암 환자 수 증가, 그리고 새롭고 혁신적이며 기술적으로 정교한 치료법의 등장 등이 모두 단일클론 항체 치료제의 세계 시장 성장에 기여하고 있습니다.

또한, 2023년 1월 5일, 니르세비맙(Nirsevimab)의 생물학적 제제 허가 신청(BLA)이 미국 식품의약국(FDA) 산하 의약품 평가 연구 센터(CDER)에서 승인되었습니다. 이 약물은 두 번째 호흡기 세포융합 바이러스(RSV) 유행 기간 동안 중증 RSV 질환 발병 위험이 있는 24개월 미만 영유아와 첫 번째 RSV 유행 기간에 접어들거나 이미 RSV를 겪고 있는 영유아 및 신생아 치료에 사용됩니다. 이처럼 바이오제약 회사들이 출시하는 새로운 치료법의 증가가 단일클론 항체 치료제 시장 성장을 견인하고 있습니다.
생명공학 기업의 연구 개발 투자 증가는 제조업체에 수익성 높은 기회를 창출합니다.
주요 기업 또는 생명공학 기업들이 독창적인 기술 혁신을 위해 연구 개발 역량에 대한 지출 또는 투자를 늘리면서 단일클론 항체 치료제 시장의 기회가 확대되고 있습니다. 단일클론 항체 치료제 시장 성장을 이끄는 또 다른 요인은 호흡기 질환의 발생률 증가입니다.

또한, 2023년 4월, 얀센 바이오테크(Janssen Biotech, Inc.)와 뉴욕대학교 그로스만 의과대학(NYU Grossman School of Medicine) 연구진이 수행한 초기 실험에서 생명공학적으로 개발된 약물 후보 물질이 황색포도상구균(Staphylococcus aureus) 감염을 예방할 수 있음을 입증했습니다.
이 보고서는 황색포도상구균에 부착하여 면역 세포가 흡수 및 제거할 수 있도록 식별하는 단백질의 일종인 유전자 조작 인간 단일클론 항체(mAb)에서 유래한 복합 분자인 mAbtyrins에 대한 예비 평가를 자세히 설명합니다. mAb에 부착된 작은 단백질인 센티린(centyrins)은 이러한 세균이 숨어 있는 인체 면역 세포에 구멍을 뚫는 것을 막습니다.

높은 비용과 엄격한 규제 조치는 시장 성장을 저해할 것입니다.

그러나 현대 의학의 기반이 된 단일클론항체 및 재조합 단백질을 포함한 생물치료제는 여전히 중저소득 국가의 인구에게는 접근하기 어려운 실정입니다. 이는 단일클론항체 치료제가 표준 치료법보다 임상적 이점을 제공하는 경우가 많음에도 불구하고 높은 비용 때문이며, 이러한 높은 비용은 단일클론항체 치료제 시장의 성장을 저해하는 요인으로 작용합니다.
단일클론항체의 연평균 비용은 96,731달러였으며, 34개의 단일클론항체-적응증 조합의 경우 10만 달러를 초과했습니다. 승인된 단일클론항체-적응증 조합의 40%를 차지하는 혈액학 및 종양학 단일클론항체는 10만 달러 이상의 가격표가 붙은 조합의 85% 이상을 차지했습니다. 따라서 위에서 언급한 요인들은 단일클론항체 치료제 시장의 성장을 제한하고 있습니다.
COVID-19 영향 분석
COVID-19 팬데믹과 전 세계 여러 국가의 봉쇄 조치는 모든 산업 분야의 기업 재정 건전성에 영향을 미쳤습니다. 따라서, 코로나19 공중보건 비상사태 기간 동안 미국 식품의약국(FDA)은 임상시험 참여자의 안전을 보장하고, 우수 임상시험관리기준(GCP)을 준수하며, 임상시험의 무결성에 대한 위험을 최소화하는 등, 스폰서와 연구자를 지원하기 위한 일반적인 고려 사항을 포함하는 지침을 발표했습니다.
이러한 치료용 단클론 항체는 코로나19 치료에도 사용되었습니다. 예를 들어, 2022년 2월 11일 일라이 릴리(Eli Lilly and Company)는 오미크론 변이체에 대한 중화 작용을 나타내는 항체인 베브텔로비맙(Bebtelovimab)이 미국 식품의약국(FDA)으로부터 긴급사용승인(EUA)을 받았다고 발표했습니다.
러시아-우크라이나 전쟁 영향 분석
러시아-우크라이나 분쟁은 해당 지역의 주요 시장 참여자 수가 적기 때문에 전 세계 단클론 항체 치료제 시장에 미치는 영향이 미미할 것으로 예상됩니다. 그러나 원자재 수출입의 영향은 예측 기간 동안 전 세계 단클론 항체 치료제 시장 성장에 거의 영향을 미치지 않을 것으로 예상됩니다.

세그먼트 분석
글로벌 단일클론항체 치료제 시장은 제품 유형, 적용 분야, 생산원, 유통 채널 및 지역별로 세분화됩니다.
생산원 부문 중 휴머노이드 항체는 신제품 출시 증가에 힘입어 시장 점유율의 45.79%를 차지합니다.
인간화 항체는 천연 마우스 단일클론항체에 비해 세 가지 장점을 가지고 있습니다. 첫째, 면역원성이 낮습니다(면역 반응이 주로 마우스 Ig 불변 영역을 표적으로 하기 때문입니다). 둘째, 인간의 효과기능을 수행할 수 있습니다. 셋째, 인체 내 혈청 반감기가 훨씬 깁니다. 연구자들은 관련 인간 항원을 표적으로 하는 마우스 CDR을 추출하여 인간 항체 골격에 조립함으로써 이러한 항체를 더욱 인간화했습니다.
티슬레리주맙(tislelizumab)이라는 인간화 IgG4 항PD-1 단일클론항체는 단독 요법 및 다른 치료법과의 병용 요법으로 연구되고 있습니다. 수술 불가능한 재발성 전이성 또는 국소 진행성 식도 편평세포암(ESCC)의 치료는 이전에 항PD-1 면역 체크포인트 억제제인 티슬레리주맙으로 전신 치료를 받은 환자에서 가능합니다.
지역 분석
북미는 주요 업체들의 강력한 입지와 증가하는 의료 인프라 투자에 힘입어 2022년 시장 점유율의 약 40.2%를 차지했습니다.
제조업체들은 북미 지역의 단일클론 항체 치료제 수요 증가로 인해 사업 확장의 기회를 얻고 있습니다. 이 지역에는 많은 생산자와 공급업체가 있으며, 빠른 경제 발전으로 단일클론 항체 치료제의 산업 생산이 증가하여 수요가 증가했습니다.
북미는 많은 생산자와 공급업체를 보유하고 있으며, 이 지역의 빠른 경제 발전으로 산업 생산이 증가하여 단일클론 항체 치료제에 대한 수요를 촉진하고 있습니다.
새로운 제품 유형 또는 응용 분야의 등장은 시장 성장을 견인할 것입니다. 기술 발전, 규제 승인, 신제품 출시 등이 성장의 원동력입니다. 연구자들은 암이나 다양한 질환에 대한 다양한 치료 접근법에 대해 더 잘 알게 되면서 이 지역 시장이 확대되고 있습니다.
경쟁 환경
단일클론 항체 치료제 시장의 주요 글로벌 기업으로는 F. Hoffmann-La Roche, Sanofi, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Regeneron Pharmaceuticals Inc., AstraZeneca, Bayers AG 등이 있습니다.
보고서 구매 이유

• 제품 유형, 적용 분야, 생산지, 최종 사용자 및 지역별 글로벌 단일클론 항체 치료제 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 단일클론 항체 치료제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 Excel 파일로 제공됩니다.
글로벌 단일클론 항체 치료제 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The Global Monoclonal Antibody Therapeutics Market reached US$ 190,698.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 531,314.6 million by 2030. The global monoclonal antibody therapeutics market is expected to exhibit a CAGR of 14.1% during the forecast period (2023-2030).
Monoclonal antibody therapeutics (mAbs) are generated from identical antibodies (or simply antibody fragments) in a homogeneous manner. The antigen recognition site, biological interactions, affinity and downstream biologic consequences of every antibody molecule in the product are identical. This sets mAbs apart from polyclonal antibodies, which have a diverse range of protein sequences and epitope recognition
The global market for monoclonal antibody therapeutics is expanding as a result of factors including the increasing prevalence of autoimmune disorders, the growing size of the therapeutic pipeline, investment by biopharmaceutical companies and their upcoming medical approvals across countries are also creating a positive outlook for the monoclonal antibody therapeutics market growth.
Market Dynamics
Increasing Regulatory Approvals and Launch of Therapies Drive the Growth of the Monoclonal Antibody Therapeutics Market
The growing number of regulatory approvals by various regulatory bodies for different monoclonal antibodies therapeutics utilized for cancer or autoimmune diseases, the growing clinical trials by major biopharmaceutical companies, an increase in the population with cancer, and new, innovative, technologically sophisticated therapies are all contributing to the growth of the global market for monoclonal antibody therapeutics.
Furthermore, on January 5, 2023, Nirsevimab's Biologics License Application (BLA) was approved by the U.S. FDA, Center for Drug Evaluation and Research for the treatment of children up to 24 months old who are still susceptible to developing severe respiratory syncytial virus (RSV) disease throughout the second RSV season as well as for infants and newborns entering or already experiencing their first RSV season. Hence, the growing number of novel therapies launched by biopharmaceutical companies is driving the monoclonal antibody therapeutics market.
The Growing Investments in Research and Development by Biotechnology Companies Create Lucrative Opportunities for Manufacturers
Due to increasing spending or investments in research and development capabilities by key players or biotechnology businesses for unique technological breakthroughs, there is a growing market opportunity for monoclonal antibody therapeutics. Another trend driving the monoclonal antibody therapies market is the increasing occurrence of respiratory diseases.
Furthermore, in April 2023, early experiments conducted by researchers at Janssen Biotech, Inc. and NYU Grossman School of Medicine demonstrated that a bioengineered medication candidate can prevent infection with the bacterium species Staphylococcus aureus.
It details the preliminary evaluation of mAbtyrins, a combination molecule derived from an engineered human monoclonal antibody (mAb), a kind of protein that adheres to and identifies S. aureus for uptake and eradication by immune cells. Centyrins, tiny proteins that are attached to the mAb, stop these germs from drilling holes in the human immune cells where they hide.
Higher Costs and Strict Regulatory Measures will Hamper the Growth of the Market.
However, biotherapeutics, including monoclonal antibodies and recombinant proteins, which have grown into the foundation of contemporary medicine, are still largely beyond reach for populations in middle- and low-income countries, in part due to their high costs, despite often providing clinical benefits over the standard of care is a restraint for monoclonal antibody therapeutics market.
The average yearly cost of a mAb was $96,731, and for 34 mAb—indication combos, it exceeded $100,000. Despite making up 40% of the approved mAb-indication combinations, hematology and oncology mAbs accounted for over 85 percent of those with a price tag of $100,000 or higher. Hence these above mentioned factors are limiting the monoclonal antibody therapeutics market’s growth.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
These therapeutic monoclonal antibodies were also used to control COVID-19. For instance, on February 11, 2022, Eli Lilly and Company announced that Bebtelovimab, an antibody that exhibits neutralization against the Omicron variant, received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
Russia-Ukraine War Impact Analysis
The Russia-Ukraine conflict is estimated to have a low impact on the global monoclonal antibody therapeutics market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global monoclonal antibody therapeutics market growth over the forecast period.
Segment Analysis
The global monoclonal antibody therapeutics market is segmented based on product type, application, production source, distribution channel and region.
Humanoid from the Production Source Segment Accounts for 45.79% of the Market Share Owing to Rising Novel Product Launches.
A humanized antibody possesses three advantages over a native mouse mAb: it is less immunogenic (since the immune response is primarily directed against the mouse Ig constant region); it can perform human effector functions; and its serum half-life in humans is significantly longer. Researchers have extracted the mouse CDRs targeted against a relevant human antigen and assembled them in a human antibody framework to further humanize these antibodies.
A humanized IgG4 anti-PD-1 monoclonal antibody called tislelizumab is being researched as a monotherapy and in conjunction with other treatments. Treatment of inoperable recurrent metastatic or locally progressed esophageal squamous cell carcinoma (ESCC) is possible in patients who had previously received systemic therapy with the anti-PD-1 immune checkpoint inhibitor tislelizumab.
Geographical Analysis
North America Accounted for Approximately 40.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Manufacturers have chances to expand their operations in this region because of the rising demand for monoclonal antibody therapeutics for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised industrial production of monoclonal antibody therapeutics, which has increased the demand.
North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for monoclonal antibody therapeutics.
Rising new product types or applications will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals, and novel product launches. Researchers are becoming more aware of various kinds of treatment approaches for cancer or various other disorders, leading to the expansion of the market in this region.
Competitive Landscape
The major global players in the monoclonal antibody therapeutics market include F. Hoffmann-La Roche, Sanofi, Merck & Co. Inc., Pfizer Inc., GSK Plc, Eli Lily and Co., Regeneron Pharmaceuticals Inc., AstraZeneca, and Bayers AG among others.
Why Purchase the Report?
• To visualize the global monoclonal antibody therapeutics market segmentation based on product type, application, production source, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of monoclonal antibody therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global monoclonal antibody therapeutics market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Regulatory Approvals and Launch of Therapies
4.1.1.2. Rising Incidence of Cancer and Other Chronic Diseases
4.1.2. Restraints
4.1.2.1. Higher Costs and Strict Regulatory Measures
4.1.3. Opportunity
4.1.3.1. The Growing Investments in Research and Development by Biotechnology Companies
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
7.1.2. Market Attractiveness Index, By Product Type
7.2. Naked *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Fusion Protein
7.4. Antibody Fragment
7.5. Conjugate
7.6. Multi-specific
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Cancer *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Autoimmune Diseases
8.4. Infectious Diseases
8.5. Others
9. By Production Source
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
9.1.2. Market Attractiveness Index, By Production Source
9.2. Human *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Humanized
9.4. Chimeric
9.5. Others
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospital *
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Centers
10.4. Research Institutes
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. The U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. The U.K.
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
Australia
11.5.7.4. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Production Source
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. F. Hoffmann-La Roche *
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Novartis AG
13.3. Merck & Co. Inc.
13.4. Pfizer Inc.
13.5. Eli Lilly and Co. (Lilly)
13.6. Sanofi
13.7. AstraZeneca
13.8. Bayer AG
13.9. Regeneron Pharmaceuticals Inc.
13.10. GSK Plc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche, 4.	Key Developments, Novartis AG, Merck & Co. Inc., Pfizer Inc., Eli Lilly and Co. (Lilly), Sanofi, AstraZeneca, Bayer AG, Regeneron Pharmaceuticals Inc., GSK Plc

표 목록 (Tables)

List of Tables

Table 1 Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Monoclonal Antibody Therapeutics Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Monoclonal Antibody Therapeutics Market Value, By Production Source, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Monoclonal Antibody Therapeutics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Monoclonal Antibody Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 8 Global Monoclonal Antibody Therapeutics Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 10 Global Monoclonal Antibody Therapeutics Market Value, By Production Source, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 12 Global Monoclonal Antibody Therapeutics Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 14 Global Monoclonal Antibody Therapeutics Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Monoclonal Antibody Therapeutics Market Value, By Region, 2022-2031(US$ Million)

Table 16 North America Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 17 North America Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 18 North America Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 19 North America Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 20 North America Monoclonal Antibody Therapeutics Market Value, By Country, 2022-2031(US$ Million)

Table 21 South America Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 22 South America Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 23 South America Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 24 South America Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 25 South America Monoclonal Antibody Therapeutics Market Value, By Country, 2022-2031(US$ Million)

Table 26 Europe Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 27 Europe Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 28 Europe Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 29 Europe Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 30 Europe Monoclonal Antibody Therapeutics Market Value, By Country, 2022-2031(US$ Million)

Table 31 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 32 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 33 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 34 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 35 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, By Country, 2022-2031(US$ Million)

Table 36 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By Product Type, 2022-2031(US$ Million)

Table 37 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By Application, 2022-2031(US$ Million)

Table 38 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By Production Source, 2022-2031(US$ Million)

Table 39 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, By End-User, 2022-2031(US$ Million)

Table 40 F. Hoffmann-La Roche: Overview

Table 41 F. Hoffmann-La Roche: Product Portfolio

Table 42 F. Hoffmann-La Roche: Key Developments

Table 43 Novartis AG: Overview

Table 44 Novartis AG: Product Portfolio

Table 45 Novartis AG: Key Developments

Table 46 Merck & Co. Inc.: Overview

Table 47 Merck & Co. Inc.: Product Portfolio

Table 48 Merck & Co. Inc.: Key Developments

Table 49 Pfizer Inc.: Overview

Table 50 Pfizer Inc.: Product Portfolio

Table 51 Pfizer Inc.: Key Developments

Table 52 Eli Lilly and Co. (Lilly): Overview

Table 53 Eli Lilly and Co. (Lilly): Product Portfolio

Table 54 Eli Lilly and Co. (Lilly): Key Developments

Table 55 Sanofi: Overview

Table 56 Sanofi: Product Portfolio

Table 57 Sanofi: Key Developments

Table 58 AstraZeneca: Overview

Table 59 AstraZeneca: Product Portfolio

Table 60 AstraZeneca: Key Developments

Table 61 Bayer AG: Overview

Table 62 Bayer AG: Product Portfolio

Table 63 Bayer AG: Key Developments

Table 64 Regeneron Pharmaceuticals Inc.: Overview

Table 65 Regeneron Pharmaceuticals Inc.: Product Portfolio

Table 66 Regeneron Pharmaceuticals Inc.: Key Developments

Table 67 GSK Plc: Overview

Table 68 GSK Plc: Product Portfolio

Table 69 GSK Plc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 2 Global Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 3 Global Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 5 Global Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 6 Global Monoclonal Antibody Therapeutics Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Product Type, 2022-2031 (%)

Figure 8 Naked Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 9 Fusion Protein Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 10 Antibody Fragment Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 11 Conjugate Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 12 Multi-specific Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 13 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 14 Cancer Application in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 15 Autoimmune Diseases Application in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 16 Infectious Diseases Application in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 17 Others Application in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 18 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Production Source, 2022-2031 (%)

Figure 19 Human Production Source in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 20 Humanoid Production Source in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 21 Chimeric Production Source in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 22 Others Production Source in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 23 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 24 Hospitals End-User in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 25 Specialty Centers End-User in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 26 Research Institutes End-User in Global Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 27 Global Monoclonal Antibody Therapeutics Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 28 North America Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 29 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 30 Europe Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 31 South America Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 32 Middle East and Africa Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 33 North America Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 34 North America Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 35 North America Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 36 North America Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 37 North America Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 38 North America Monoclonal Antibody Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 39 South America Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 40 South America Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 41 South America Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 42 South America Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 43 South America Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 44 South America Monoclonal Antibody Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 45 Europe Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 46 Europe Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 47 Europe Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 48 Europe Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 49 Europe Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 50 Europe Monoclonal Antibody Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 51 Asia-Pacific Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 52 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 53 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 54 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 55 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 56 Asia-Pacific Monoclonal Antibody Therapeutics Market Share, By Country, 2022 & 2031 (%)

Figure 57 Middle East & Africa Monoclonal Antibody Therapeutics Market Value, 2022-2031(US$ Million)

Figure 58 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By Product Type, 2022 & 2031 (%)

Figure 59 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By Application, 2022 & 2031 (%)

Figure 60 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By Production Source, 2022 & 2031 (%)

Figure 61 Middle East & Africa Monoclonal Antibody Therapeutics Market Share, By End-User, 2022 & 2031 (%)

Figure 62 F. Hoffmann-La Roche: Financials

Figure 63 Novartis AG: Financials

Figure 64 Merck & Co. Inc.: Financials

Figure 65 Pfizer Inc.: Financials

Figure 66 Eli Lilly and Co. (Lilly): Financials

Figure 67 Sanofi: Financials

Figure 68 AstraZeneca: Financials

Figure 69 Bayer AG: Financials

Figure 70 Regeneron Pharmaceuticals Inc.: Financials

Figure 71 GSK Plc: Financials

글로벌 단일클론항체 치료제 시장 – 2023-2030

Global Monoclonal Antibody Therapeutics Market - 2023-2030